FluoGuide A/S (STO:FLUO)

Sweden flag Sweden · Delayed Price · Currency is SEK
41.20
+0.10 (0.24%)
Aug 1, 2025, 5:29 PM CET
0.24%
Market Cap559.79M
Revenue (ttm)574.48K
Net Income (ttm)-44.06M
Shares Out13.62M
EPS (ttm)-3.30
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume4,693
Average Volume8,166
Open40.50
Previous Close41.10
Day's Range40.00 - 41.50
52-Week Range29.10 - 57.00
Beta1.10
RSI48.00
Earnings DateAug 28, 2025

About ANSYS

FluoGuide A/S, a clinical stage biotechnology company, focuses on developing drugs for surgical outcomes by making cancer fluorescent in Denmark. Its lead product candidate is FG001, which is in Phase IIa and IIb for the treatment of high-grade glioma; Phase II clinical trial for the treatment of lung cancer, and head and neck cancer. FluoGuide A/S was incorporated in 2018 and is headquartered in Copenhagen, Denmark. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2018
Employees 8
Stock Exchange Nasdaq Stockholm
Ticker Symbol FLUO
Full Company Profile

Financial Performance

In 2024, FluoGuide's revenue was 385,000, a decrease of -8.98% compared to the previous year's 423,000. Losses were -28.96 million, -24.54% less than in 2023.

Financial Statements

News

There is no news available yet.